뇌부종 : 파이프라인 리뷰

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

뇌부종(Brain Edema) 치료제 개발 상황에 대해 조사했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 및 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스 및 프레스 릴리스 등의 정보를 전해드립니다.

서론

• 조사 범위

뇌부종 개요

치료제 개발

• 파이프라인 제품 개요
• 파이프라인 제품 비교 분석

뇌부종 : 기업에서 개발중인 치료제

뇌부종 : 대학/기관에서 연구중인 치료제

뇌부종 : 파이프라인 제품 개요

• 임상 단계 제품
• 초기 단계 제품

뇌부종 : 기업에서 개발중인 제품

뇌부종 : 대학/기관에서 연구중인 제품

뇌부종 치료제 개발에 참여하고 있는 기업

• FibroGen, Inc.
• Pharmazz, Inc.
• Remedy Pharmaceuticals, Inc.

뇌부종 : 치료제 평가

• 단독치료 제품(Monotherapy Products)별
• 표적별
• 작용기서별
• 투여 경로별
• 분자 종류별

약제 개요

뇌부종 : 최근의 파이프라인 동향

뇌부종 : 휴지중인 프로젝트

뇌부종 : 제품 개발 마일스톤

• 주요 뉴스와 프레스 릴리스

부록

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Brain Edema - Pipeline Review, H2 2016, provides an overview of the Brain Edema (Central Nervous System) pipeline landscape.

Brain swelling is enlargement of the brain due to excessive fluid collection in the chambers, or ventricles, of the brain or the accumulation of fluid within the brain tissue itself. Cause of brain swelling includes traumatic brain injury (tbi), ischemic stroke, hemorrhages, tumors and infections (toxoplasmosis, meningitis, subdural empyema). Symptoms include headache, neck pain or stiffness, nausea or vomiting, dizziness, irregular breathing, vision loss or changes, memory loss, inability to walk, difficulty speaking, stupor, seizures and loss of consciousness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Brain Edema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Edema (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Edema (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Brain Edema.

Brain Edema (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Edema (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Brain Edema (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Brain Edema (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Brain Edema (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Brain Edema (Central Nervous System)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Brain Edema (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Brain Edema (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

• Table of Contents
  • List of Tables
  • List of Figures
• Introduction
  • Global Markets Direct Report Coverage
• Brain Edema Overview
• Therapeutics Development
  • Pipeline Products for Brain Edema - Overview
  • Pipeline Products for Brain Edema - Comparative Analysis
• Brain Edema - Therapeutics under Development by Companies
• Brain Edema - Therapeutics under Investigation by Universities/Institutes
• Brain Edema - Pipeline Products Glance
  • Clinical Stage Products
  • Early Stage Products
• Brain Edema - Products under Development by Companies
• Brain Edema - Products under Investigation by Universities/Institutes
• Brain Edema - Companies Involved in Therapeutics Development
  • FibroGen Inc
  • Pharmazz Inc
  • Remedy Pharmaceuticals Inc
• Brain Edema - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
• Drug Profiles
  • Drugs to Modulate Aquaporin Channels for Brain Edema and Cancer - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • FG-4497 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • glyburide - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • PMZ-2123 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Small Molecules to Block Aquaporin-4 for Brain Edema - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
• Brain Edema - Dormant Projects
• Brain Edema - Product Development Milestones
  • Featured News & Press Releases
    • Jun 08, 2016: Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA
    • Apr 11, 2016: Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting
    • Apr 06, 2016: Remedy Pharmaceuticals Issues First Quarter 2016 Report
    • Mar 04, 2016: Remedy Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA on a Novel Drug Treatment for CNS-Related Edema
    • Feb 22, 2016: Remedy Pharmaceuticals Announces Additional Results From Phase 2 CNS-Related Edema Study of CIRARA Presented at International Stroke Conference
    • Feb 08, 2016: Remedy Pharmaceuticals Announces Acceptance of Two Oral Presentations on Phase 2 Results of CIRARA for CNS-Related Edema at ISC 2016
    • Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial
• Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

• Number of Products under Development for Brain Edema, H2 2016
• Number of Products under Development for Brain Edema - Comparative Analysis, H2 2016
• Number of Products under Development by Companies, H2 2016
• Number of Products under Investigation by Universities/Institutes, H2 2016
• Comparative Analysis by Clinical Stage Development, H2 2016
• Comparative Analysis by Early Stage Development, H2 2016
• Products under Development by Companies, H2 2016
• Products under Investigation by Universities/Institutes, H2 2016
• Brain Edema - Pipeline by FibroGen Inc, H2 2016
• Brain Edema - Pipeline by Pharmazz Inc, H2 2016
• Brain Edema - Pipeline by Remedy Pharmaceuticals Inc, H2 2016
• Assessment by Monotherapy Products, H2 2016
• Number of Products by Stage and Target, H2 2016
• Number of Products by Stage and Mechanism of Action, H2 2016
• Number of Products by Stage and Route of Administration, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016
• Brain Edema - Dormant Projects, H2 2016

List of Figures

• Number of Products under Development for Brain Edema, H2 2016
• Number of Products under Development for Brain Edema - Comparative Analysis, H2 2016
• Number of Products under Development by Companies, H2 2016
• Comparative Analysis by Early Stage Products, H2 2016
• Assessment by Monotherapy Products, H2 2016
• Number of Products by Targets, H2 2016
• Number of Products by Stage and Targets, H2 2016
• Number of Products by Mechanism of Actions, H2 2016
• Number of Products by Stage and Mechanism of Actions, H2 2016
• Number of Products by Stage and Routes of Administration, H2 2016
• Number of Products by Molecule Types, H2 2016
• Number of Products by Stage and Molecule Types, H2 2016